Assessment of economic and humanistic burden of refractory chronic spontaneous/idiopathic urticaria: Study design of the first observational study, ASSURE-CSU - 09/05/15
Gordon Sussman, MD, Division of Allergy and Clinical Immunology, St Michael’s Hospital, University of Toronto, Toronto, Canada; Marcus Maurer, MD, Charité – Universitätsmedizin Berlin, Department of Dermatology and Allergy, Berlin, Germany; Karsten Weller, MD, Charité – Universitätsmedizin Berlin, Department of Dermatology and Allergy, Berlin, Germany; Alla Nakonechna, MD, PhD, Department of Immunology, Hull Royal Infirmary, Hull and East Yorkshire NHS Hospital Trust, Hull, United Kingdom; Mohamed Abouzakouk, MD, PhD, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; Kelly Hollis, MBA, RTI Health Solutions, Raleigh, NC, United States; Doreen McBride, PhD, MBA, RTI Health Solutions, Manchester, United Kingdom; Maria-Magdalena Balp, MD, Novartis Pharma AG, Basel, Switzerland; Frédéric Berard, MD, PhD, Clinical Immunology and Allergology CH Lyon-Sud Claude Bernard University Lyon I, Lyon, France; Ana M. Giménez-Arnau, MD, PhD, Department of Dermatology, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain; Javier Ortiz de Frutos, MD, Dermatology Department, Hospital 12 de Octubre, Madrid, Spain; Giorgio Walter Canonica, MD, Allergy and Respiratory Diseases, DIMI, Department of Internal Medicine, University of Genoa, Genoa, Italy; André C. Knulst, MD, PhD, Department of Dermatology/Allergology, University Medical Center Utrecht, Utrecht, Netherlands
Le texte complet de cet article est disponible en PDF. This study was funded by Novartis and Genentech, Inc. |
Vol 72 - N° 5S1
P. AB41 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?